Dr. Steven Polyak, MD
Claim this profileHolden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics
Affiliated Hospitals
Holden Comprehensive Cancer Center, University Of Iowa Hospitals And Clinics
University Of Iowa Hospitals And Clinics
Clinical Trials Steven Polyak, MD is currently running
Obefazimod
for Crohn's Disease
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.
Recruiting
0 awards
Phase 2
4 criteria
TAK-279
for Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.
Recruiting
0 awards
Phase 2
4 criteria
More about Steven Polyak, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Steven Polyak, MD has experience with
- TAK-279
- ABX464
- CDPATH™
- Placebo
- BMS-986165
- Obefazimod
Breakdown of trials Steven Polyak, MD has run
Crohn's Disease
Ulcerative Colitis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven Polyak, MD specialize in?
Steven Polyak, MD focuses on Crohn's Disease and Ulcerative Colitis. In particular, much of their work with Crohn's Disease has involved treating patients, or patients who are undergoing treatment.
Is Steven Polyak, MD currently recruiting for clinical trials?
Yes, Steven Polyak, MD is currently recruiting for 2 clinical trials in Iowa City Iowa. If you're interested in participating, you should apply.
Are there any treatments that Steven Polyak, MD has studied deeply?
Yes, Steven Polyak, MD has studied treatments such as TAK-279, ABX464, CDPATH™.
What is the best way to schedule an appointment with Steven Polyak, MD?
Apply for one of the trials that Steven Polyak, MD is conducting.
What is the office address of Steven Polyak, MD?
The office of Steven Polyak, MD is located at: Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242 United States. This is the address for their practice at the Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.